NVAX Stock Price: Novavax Inc drops as big name biotech companies inch closer to EUA for COVID-19 vaccine

NASDAQ:NVAX falls by 4.08% amidst a broader market selloff stimulus talks stumble in America.
Novavax teams with UC Davis Health to test its coronavirus vaccine candidate.
COVID-19 vaccine makers watch on as Pfizer expects EUA on Thursday from the FDA.

Stocks Reporter FXStreet

NASDAQ:NVAX has been somewhat forgotten in the race for Emergency Use Authorization (EUA) of its COVID-19 vaccine, taking a backseat to some of the biotech giants who are anticipating approval over the next couple of weeks. Novavax dropped 4.08% on Wednesday alongside a broader market selloff as US stimulus talks hit another wall in Congress. Investors do not have much to complain about considering shares are still up nearly 3000% over the past 52-weeks, with more to come in 2021 once its COVID-19 vaccine is approved for distribution.

Novavax announced it is teaming with UC Davis Health to begin a Stage 3 clinical trial that will hopefully mean that its COVID-19 vaccine candidate NVX-CoV2373 will be approved and ready to be distributed by early to midway through 2021. For its part, Novavax has already secured some massive deals including 1 billion doses for India, whenever the vaccine can be produced. The Maryland-based biotech firm also has deals in place with Australia and Canada, amongst other countries, so 2021 could be lining up as a big year for Novavax, which still only commands a $7 billion market cap.

NVAX stock news

While Novavax is lagging behind leaders like Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA), early results from its clinical trials had some analysts labelling Novavax as the company to beat in Operation Warp Speed. Pfizer and Moderna will have the first-mover advantage and are already the brands synonymous with ridding the world of COVID-19, but by the end of it, Novavax should be there as well and that is already evident in the large orders it has received.

Premium

You have reached your limit of 3 free articles for this month.

Start your subscription and get access to all our original articles.

Subscribe to Premium Sign In

Author

Stocks Reporter

FXStreet

GBP/USD gathers strength above 1.3350, but stays capped below 100-day average

The GBP/USD pair trades in positive territory around 1.3360 during the early European session on Friday. The British Pound gathers strength against the US Dollar on a weaker-than-expected US Nonfarm Payrolls report.

EUR/USD trades cautiously higher near mid-1.1400s amid mixed setup

The EUR/USD pair attracts some dip-buyers during the Asian session on Friday, stalling the previous day's modest pullback from the 1.1470-1.1475 region, or a nearly two-week high. Spot prices currently trade just below mid-1.1400s and seem poised to register gains for the first time in three weeks as receding US Federal Reserve rate hike bets keep the US Dollar depressed.

Gold advances to $4,200 neighborhood amid reduced Fed hike bets

Gold is seen building on this week's recovery move from its lowest level since November 2025 and gaining positive traction for the third straight day. The precious metal advances to the $4,200 neighborhood, or a one-and-a-half-week high, during the Asian session and remains on track to register gains for the first time in five weeks.

Bitcoin and Ethereum rebound as bulls return, XRP targets breakout

Bitcoin, Ethereum and Ripple extend their recovery on Friday as improving risk sentiment and strengthening technical indicators support the broader cryptocurrency market. BTC reclaims the $61,300 level after rebounding from a 21-month low earlier this week, while ETH holds firm near $1,700 following a sharp two-day recovery.

Economics week ahead

Market attention turns to next week's FOMC minutes for any signs of what could shift a divided Committee from a hold toward rate hikes. The dot plot from the last meeting made clear that policymakers are split on whether rate hikes are warranted, but with forward guidance getting tamped down under Chair Warsh, the Fed's reaction function remains uncertain in terms of what exactly would build broader support for more restrictive policy.

Kevin Warsh offers no policy clues: Why markets still got their answer

Financial markets came to Sintra looking for clues about the Federal Reserve's (Fed) next move. They largely left with confirmation that Fed Chair Kevin Warsh intends to make those clues much harder to find.